{"nctId":"NCT01599104","briefTitle":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","startDateStruct":{"date":"2012-06"},"conditions":["Essential Hypertension"],"count":1161,"armGroups":[{"label":"LCZ696 200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696","Drug: Placebo"]},{"label":"LCZ696 400 mg","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696","Drug: Placebo"]},{"label":"Olmesartan 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olmesartan","Drug: Placebo"]}],"interventions":[{"name":"LCZ696","otherNames":[]},{"name":"Olmesartan","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with mild-to-moderate hypertension, untreated or currently taking antihypertensive therapy.\n* Treated patients (using antihypertensive treatments within 4 weeks prior to Visit 1) must have an msSBP ≥ 150 mmHg and \\< 180 mmHg at the randomization visit (Visit 201) and msSBP ≥140 mmHg \\< 180 mmHg at the visit immediately proceeding Visit 201 (Visit 102 or 103).\n* Untreated patients (newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to Visit 1) must have an msSBP ≥ 150 mmHg and \\< 180 mmHg at both Visit 1 and Visit 201.\n* Patients must have an absolute difference of ≤15 mmHg in msSBP between Visit 201 and the immediately preceding visit;\n\nExclusion Criteria:\n\n* Severe hypertension (msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg).\n* History of angioedema, drug-related or otherwise, as reported by the patient.\n* History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension.\n* Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)","description":"Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.21","spread":"0.702"},{"groupId":"OG001","value":"-20.18","spread":"0.704"},{"groupId":"OG002","value":"-13.20","spread":"0.700"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean 24-hour Ambulatory SBP (maSBP) at Week 8","description":"Ambulatory blood pressure monitoring (ABPM) over a 24-hour period was conducted at two time-points during the study in a subset of participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.44","spread":"0.445"},{"groupId":"OG001","value":"-14.99","spread":"0.445"},{"groupId":"OG002","value":"-8.78","spread":"0.462"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)","description":"Sitting BP measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.76","spread":"0.404"},{"groupId":"OG001","value":"-8.79","spread":"0.406"},{"groupId":"OG002","value":"-5.91","spread":"0.404"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Successful Response in Overall Blood Pressure Control at Week 8","description":"A successful response in overall BP control rate was defined as msSBP \\< 140 mmHg and msDBP \\<90 mmHg.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"46.5","spread":null},{"groupId":"OG002","value":"32.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Successful msSBP Response","description":"Successful msSBP response was defined as \\< 140 mmHg or ≥ 20 mmHg reduction from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":null},{"groupId":"OG001","value":"63.1","spread":null},{"groupId":"OG002","value":"42.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Successful msDBP Response","description":"Successfull msDBP response was defined as \\<90 mmHg or ≥10 mmHg reduction from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null},{"groupId":"OG001","value":"70.1","spread":null},{"groupId":"OG002","value":"60.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean 24-hour Ambulatory DBP (maDBP) at Week 8","description":"ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.65","spread":"0.295"},{"groupId":"OG001","value":"-8.44","spread":"0.295"},{"groupId":"OG002","value":"-5.56","spread":"0.307"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in maSBP and maDBP for Daytime/Nighttime","description":"ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.60","spread":"0.747"},{"groupId":"OG001","value":"-14.44","spread":"0.747"},{"groupId":"OG002","value":"-7.87","spread":"0.776"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.13","spread":"0.747"},{"groupId":"OG001","value":"-16.09","spread":"0.747"},{"groupId":"OG002","value":"-10.65","spread":"0.776"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.01","spread":"0.506"},{"groupId":"OG001","value":"-8.00","spread":"0.506"},{"groupId":"OG002","value":"-4.95","spread":"0.526"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.82","spread":"0.506"},{"groupId":"OG001","value":"-9.42","spread":"0.506"},{"groupId":"OG002","value":"-6.79","spread":"0.526"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Office Pulse Pressure","description":"Office pulse pressure was calculated as msSBP minus msDBP. Sitting blood pressure (BP) measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and then averaged to calculate the mean BP value. The baseline PP value was subtracted from the week 8 PP value to determine the change from baseline in PP.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.49","spread":"0.471"},{"groupId":"OG001","value":"-11.30","spread":"0.472"},{"groupId":"OG002","value":"-7.34","spread":"0.470"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure","description":"Ambulatory pulse pressure was calculated as hourly ambulatory SBP minus hourly ambulatory DBP in a subset of participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.79","spread":"0.208"},{"groupId":"OG001","value":"-6.57","spread":"0.207"},{"groupId":"OG002","value":"-3.20","spread":"0.216"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Events, Serious Adverse Events and Death","description":"Participants were monitored for adverse events, serious adverse events and deaths throughout the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"136","spread":null},{"groupId":"OG002","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":387},"commonTop":["NASOPHARYNGITIS"]}}}